Anticoagulation drug therapy is prescribed in patients who are suffering from a venous atrial fibrillation (AF), thromboembolism, mechanical valve replacement, and other coagulation disorders such as antiphospholipid antibody syndrome and Factor V Leiden. In some instances, such as unexpected surgery or anticoagulant overdose, anticoagulant reversal drugs are necessary to reverse the impact of anticoagulation. Increased frequency of cerebral & gastrointestinal haemorrhage and new technology add-on status (NTAP) granted to certain medicines, which focuses on the development of specialised drugs for anticoagulation reversal. Fresh frozen plasma is frequently used to counteract the effects of warfarin, although complete reversal takes six to 24 hours. Prothrombin complex concentrates (PCCs) can be utilised in more urgent situations since they give full anticoagulation reversal in 15-20 minutes.
Several reversal medicines have been developed for patients using newer oral anticoagulants. However, it should be emphasised that these newer anticoagulants have short half-lives (5-17 hours), and reversal is rarely indicated. Reversal medicines have a risk of life-threatening thrombosis and should be used only under the supervision of a professional with experience in their usage and/or in a patient who is at urgent danger of death from bleeding. In most cases, a single dosage is administered. However, dosing may be repeated in exceptional cases when the oral anticoagulant remains in the blood for a prolonged period of time, such as severe renal failure.
Market Dynamics
Increasing spending in research and development is anticipated to propel the anticoagulant reversal drugs market growth during the forecast period. For instance, in December 2020, Octa Pharma USA released the findings of clinical study conducted to assess the safety and efficacy of fibryga, a Human Fibrinogen Lyophilized Powder for Reconstitution recommended for intravenous use in the treatment of congenital and acquired bleeding disorders, in the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.
Key features of the study:
- This report provides an in-depth analysis of the global anticoagulant reversal drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global anticoagulant reversal drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Portola Pharmaceuticals, Boehringer Ingelheim, CSL Behring, Bausch Health Companies Inc., Octapharma AG, Dr. Reddy's Laboratories, AMAG Pharmaceuticals, Inc., Pfizer, Inc., SGPharma Pvt. Ltd., Alps Pharmaceutical Ind. Co., Ltd., Fresenius Kabi AG, Mundipharma International Limited, and Hisamitsu Pharmaceutical Co., Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global anticoagulant reversal drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global anticoagulant reversal drugs market
Detailed Segmentation:
- Global Anticoagulant Reversal Drugs Market, By Product Type:
- Idarucizumab
- Protamine
- Prothrombin Complex Concentrates
- Phytonadione
- Andexanet Alfa
- Others
- Global Anticoagulant Reversal Drugs Market, By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Global Anticoagulant Reversal Drugs Market, By Region:
- North America
- By Product Type
- Idarucizumab
- Protamine
- Prothrombin Complex Concentrates
- Phytonadione
- Andexanet Alfa
- Others
- By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- By Country
- Latin America
- By Product Type
- Idarucizumab
- Protamine
- Prothrombin Complex Concentrates
- Phytonadione
- Andexanet Alfa
- Others
- By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Product Type
- Idarucizumab
- Protamine
- Prothrombin Complex Concentrates
- Phytonadione
- Andexanet Alfa
- Others
- By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Product Type
- Idarucizumab
- Protamine
- Prothrombin Complex Concentrates
- Phytonadione
- Andexanet Alfa
- Others
- By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Product Type
- Idarucizumab
- Protamine
- Prothrombin Complex Concentrates
- Phytonadione
- Andexanet Alfa
- Others
- By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Product Type
- Idarucizumab
- Protamine
- Prothrombin Complex Concentrates
- Phytonadione
- Andexanet Alfa
- Others
- By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- By Country/Region
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Portola Pharmaceuticals *
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Boehringer Ingelheim
- CSL Behring
- Bausch Health Companies Inc.
- Octapharma AG
- Reddy's Laboratories
- AMAG Pharmaceuticals, Inc.
- Pfizer, Inc.
- SGPharma Pvt. Ltd.
- Alps Pharmaceutical Ind. Co., Ltd.
- Fresenius Kabi AG
- Mundipharma International Limited
- Hisamitsu Pharmaceutical Co., Inc.
“*” marked represents similar segmentation in other categories in the respective section.
